Effects of hemoperfusion treatment on serum IL-23 and IL-17 levels in children with Henoch-Schönlein purpure.
- Author:
Li LIU
1
;
Yan-Ping HUANG
;
Xia-Ling FANG
;
Yuan-Yuan ZHANG
;
Ning CHEN
;
Hong-Hong HOU
Author Information
- Publication Type:Journal Article
- MeSH: Child; Child, Preschool; Female; Hemoperfusion; Humans; Interleukin-17; blood; physiology; Interleukin-23; blood; physiology; Male; Purpura, Schoenlein-Henoch; immunology; therapy
- From: Chinese Journal of Contemporary Pediatrics 2015;17(8):796-799
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effects of hemoperfusion treatment on serum interleukin-17 (IL-17) and IL-23 levels in children with Henoch-Schönlein purpura (HSP).
METHODSEighty-seven children who were diagnosed with HSP and who had received hemoperfusion treatment between January 2011 and December 2012 were enrolled. Twenty-seven sex- and age-matched healthy children were recruited as normal controls. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum concentrations of IL-17 and IL-23.
RESULTSThe serum IL-23 and IL-17 levels in the HSP group were significantly higher than in the control group (P<0.05). After hemoperfusion treatment, the serum IL-23 and IL-17 levels in the HSP group were significantly reduced to the levels of the control group. Serum serum IL-17 level was positively correlated with serum IL-23 level (P<0.05) in children with HSP.
CONCLUSIONSHemoperfusion treatment can reduce serum IL-23 and IL-17 levels in children with HSP, suggesting that the treatment may be effective for HSP.
